サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1637030

重症筋無力症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

出版日
ページ情報
英文 230 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
重症筋無力症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）
出版日: 2025年01月16日
発行: Fairfield Market Research
ページ情報: 英文 230 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の重症筋無力症（MG）治療市場は、8.2％のCAGRで拡大し、大幅な成長が見込まれています。市場規模は2025年の26億9,000万米ドルから2032年には46億7,000万米ドルに急増すると予測されています。このような上昇軌道は、治療手法の技術的進歩や重症筋無力症に対する意識の高まりが後押ししています。

重症筋無力症（MG）は神経筋自己免疫疾患であり、神経と筋肉間の情報伝達の障害により筋力低下や疲労を引き起こします。治療の第一目標は、神経筋のトランスミッションを強化し、自己免疫活性を抑制することです。利用可能な治療戦略には、アセチルコリンエステラーゼ阻害剤、免疫抑制剤、革新的なモノクローナル抗体療法などがあります。

特に高齢者層におけるMGの有病率の上昇と精密医療への関心の高まりは、市場拡大の主な要因です。さらに、製薬企業と研究機関の共同研究により、次世代標的治療薬の開発が急ピッチで進められています。

エクリズマブやリツキシマブなどのモノクローナル抗体は、特定の免疫成分を標的とすることでMG治療に革命をもたらし、より効果的な疾患管理につながっています。免疫療法の継続的な進歩により、複雑な免疫学的要因に対処する能力が強化され、より正確で効果的な治療オプションが提供されています。

当レポートでは、世界の重症筋無力症治療市場について調査し、市場の概要とともに、薬剤クラス別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナ・ロシア紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の重症筋無力症治療市場の見通し、2019年～2032年

  • 世界の重症筋無力症治療市場の見通し、薬剤クラス別、金額（10億米ドル）、2019年～2032年
  • 世界の重症筋無力症治療市場の見通し、流通チャネル別、金額（10億米ドル）、2019年～2032年
  • 世界の重症筋無力症治療市場の見通し、地域別、金額（10億米ドル）、2019年～2032年

第4章 北米の重症筋無力症治療市場の見通し、2019年～2032年

第5章 欧州の重症筋無力症治療市場の見通し、2019年～2032年

第6章 アジア太平洋の重症筋無力症治療市場の見通し、2019年～2032年

第7章 ラテンアメリカの重症筋無力症治療市場の見通し、2019年～2032年

第8章 中東・アフリカの重症筋無力症治療市場の見通し、2019年～2032年

第9章 競合情勢

  • 企業市場シェア分析、2025年
  • 競合ダッシュボード
  • 企業プロファイル
    • Grifols SA
    • Pfizer, Inc.
    • AbbVie Inc.
    • GSK
    • Novartis AG
    • Alexion Pharmaceutical Inc.
    • F. Hoffman-La Roche Ltd.
    • Bausch Health Companies Inc.
    • Shire plc.
    • Avadel Pharmaceuticals plc.

第10章 付録

目次

The global myasthenia gravis (MG) treatment market is poised for substantial growth, with projections indicating an 8.2% compound annual growth rate (CAGR). The market size is expected to surge from USD 2.69 billion in 2025 to USD 4.67 billion by 2032. This upward trajectory is fueled by technological advancements in treatment methodologies and rising awareness about MG.

Overview of Myasthenia Gravis and Treatment Approaches

Myasthenia gravis (MG) is a neuromuscular autoimmune disorder that leads to muscle weakness and fatigue due to disrupted communication between nerves and muscles. The primary goal of treatment is to enhance neuromuscular transmission and suppress autoimmune activity. Available therapeutic strategies include acetylcholinesterase inhibitors, immunosuppressive drugs, and innovative monoclonal antibody therapies.

The increasing prevalence of MG, particularly among the aging demographic, and the growing focus on precision medicine are key drivers of market expansion. Moreover, collaborations between pharmaceutical companies and research institutions are fast-tracking the development of next-generation targeted treatments.

Key Market Growth Drivers

1. Breakthroughs in Immunotherapy

  • Monoclonal antibodies, such as eculizumab and rituximab, are revolutionizing MG treatment by targeting specific immune components, leading to more effective disease management.
  • Ongoing advancements in immunotherapy are enhancing the ability to address complex immunological factors, providing more precise and effective treatment options.

2. Increasing Awareness and Early Diagnosis

  • Enhanced diagnostic tools and public health initiatives are facilitating earlier detection of MG, improving patient outcomes.
  • Greater recognition among healthcare professionals and public awareness campaigns are boosting demand for effective treatment solutions.

Emerging Business Opportunities

1. Expansion of Personalized Treatment Strategies

  • Precision medicine is reshaping MG treatment by customizing therapies based on individual genetic profiles. This approach enhances treatment efficacy and minimizes side effects.
  • Advancements in immunogenetics and biotechnology are fostering the development of personalized therapeutic solutions.

2. Innovation in Treatment Modalities

  • Companies exploring new treatment avenues, such as gene therapies and advanced immunomodulators, have the potential to address unmet medical needs and unlock new revenue opportunities.
  • The adoption of next-generation biologics and novel drug formulations is reshaping the competitive Analysisof MG treatment.

Regional Market Insights

1. Europe: A Hub for Advanced MG Treatments

  • Europe leads the market due to its robust healthcare infrastructure and supportive regulatory framework.
  • Cutting-edge diagnostic facilities and specialized neurological care centers are driving rapid adoption of advanced MG treatments.
  • The European Medicines Agency's (EMA) proactive policies bolster investment confidence and accelerate drug development initiatives.

2. South Asia & Pacific: Fastest-Growing Market

  • Rapid population growth, along with an increasing prevalence of MG, is fueling demand for effective treatment solutions in this region.
  • Expanding healthcare access, coupled with rising awareness campaigns, is encouraging early diagnosis and treatment adoption.

Market Challenges and Barriers

1. Regulatory Hurdles

  • Stringent approval processes for new MG drugs can delay market entry, making regulatory compliance a critical challenge for pharmaceutical firms.
  • Companies must navigate complex approval requirements to maintain a competitive edge.

2. Complexity of MG Treatment

  • Due to MG's heterogeneous nature, treatment protocols must be personalized, making standardization difficult.
  • The need for individualized treatment plans increases the complexity of drug development and clinical trials.

Competitive Landscape: Key Industry Players

Several leading pharmaceutical companies are actively engaged in developing and commercializing MG treatments, including:

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc

These companies are investing in research and development (R&D) to introduce next-generation therapies and expand their market presence.

Market Segmentation: Key Categories

1. By Drug Class

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulin (IVIg)
  • Monoclonal Antibodies

2. By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

3. By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Myasthenia Gravis Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2025
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 3.1. Global Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 3.1.1. Key Highlights
      • 3.1.1.1. Corticosteroids
      • 3.1.1.2. IVIg
      • 3.1.1.3. Monoclonal Antibodies
      • 3.1.1.4. Immunosuppressants
      • 3.1.1.5. Cholinesterase Inhibitors
  • 3.2. Global Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Retail Pharmacies
      • 3.2.1.3. Online Pharmacies
  • 3.3. Global Myasthenia Gravis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 4.1. North America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 4.1.1. Key Highlights
      • 4.1.1.1. Corticosteroids
      • 4.1.1.2. IVIg
      • 4.1.1.3. Monoclonal Antibodies
      • 4.1.1.4. Immunosuppressants
      • 4.1.1.5. Cholinesterase Inhibitors
  • 4.2. North America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Retail Pharmacies
      • 4.2.1.3. Online Pharmacies
  • 4.3. North America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 4.3.1. Key Highlights
      • 4.3.1.1. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.2. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 4.3.1.3. Canada Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 4.3.1.4. Canada Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 5.1. Europe Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Corticosteroids
      • 5.1.1.2. IVIg
      • 5.1.1.3. Monoclonal Antibodies
      • 5.1.1.4. Immunosuppressants
      • 5.1.1.5. Cholinesterase Inhibitors
  • 5.2. Europe Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Retail Pharmacies
      • 5.2.1.3. Online Pharmacies
  • 5.3. Europe Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.2. Germany Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.3. U.K. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.4. U.K. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.5. France Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.6. France Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.7. Italy Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.8. Italy Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.9. Turkey Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.10. Turkey Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.11. Russia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.12. Russia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 5.3.1.13. Rest of Europe Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 5.3.1.14. Rest of Europe Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 6.1. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Corticosteroids
      • 6.1.1.2. IVIg
      • 6.1.1.3. Monoclonal Antibodies
      • 6.1.1.4. Immunosuppressants
      • 6.1.1.5. Cholinesterase Inhibitors
  • 6.2. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Retail Pharmacies
      • 6.2.1.3. Online Pharmacies
  • 6.3. Asia Pacific Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.2. China Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.3. Japan Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.4. Japan Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.5. South Korea Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.6. South Korea Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.7. India Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.8. India Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.9. Southeast Asia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.10. Southeast Asia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 6.3.1.11. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 6.3.1.12. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 7.1. Latin America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Corticosteroids
      • 7.1.1.2. IVIg
      • 7.1.1.3. Monoclonal Antibodies
      • 7.1.1.4. Immunosuppressants
      • 7.1.1.5. Cholinesterase Inhibitors
  • 7.2. Latin America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Retail Pharmacies
      • 7.2.1.3. Online Pharmacies
  • 7.3. Latin America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.2. Brazil Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.3. Mexico Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.4. Mexico Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.5. Argentina Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.6. Argentina Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 7.3.1.7. Rest of Latin America Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 7.3.1.8. Rest of Latin America Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, 2019 - 2032

  • 8.1. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Corticosteroids
      • 8.1.1.2. IVIg
      • 8.1.1.3. Monoclonal Antibodies
      • 8.1.1.4. Immunosuppressants
      • 8.1.1.5. Cholinesterase Inhibitors
  • 8.2. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Retail Pharmacies
      • 8.2.1.3. Online Pharmacies
  • 8.3. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.2. GCC Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.3. South Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.4. South Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.5. Egypt Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.6. Egypt Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.7. Nigeria Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.8. Nigeria Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
      • 8.3.1.9. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
      • 8.3.1.10. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Market Share Analysis, 2025
  • 9.2. Competitive Dashboard
  • 9.3. Company Profiles
    • 9.3.1. Grifols SA
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Product Portfolio
      • 9.3.1.3. Financial Overview
      • 9.3.1.4. Business Strategies and Development
    • 9.3.2. Pfizer, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Product Portfolio
      • 9.3.2.3. Financial Overview
      • 9.3.2.4. Business Strategies and Development
    • 9.3.3. AbbVie Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Financial Overview
      • 9.3.3.4. Business Strategies and Development
    • 9.3.4. GSK
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Product Portfolio
      • 9.3.4.3. Financial Overview
      • 9.3.4.4. Business Strategies and Development
    • 9.3.5. Novartis AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Product Portfolio
      • 9.3.5.3. Financial Overview
      • 9.3.5.4. Business Strategies and Development
    • 9.3.6. Alexion Pharmaceutical Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Product Portfolio
      • 9.3.6.3. Financial Overview
      • 9.3.6.4. Business Strategies and Development
    • 9.3.7. F. Hoffman-La Roche Ltd.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Product Portfolio
      • 9.3.7.3. Financial Overview
      • 9.3.7.4. Business Strategies and Development
    • 9.3.8. Bausch Health Companies Inc.
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Product Portfolio
      • 9.3.8.3. Financial Overview
      • 9.3.8.4. Business Strategies and Development
    • 9.3.9. Shire plc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Product Portfolio
      • 9.3.9.3. Financial Overview
      • 9.3.9.4. Business Strategies and Development
    • 9.3.10. Avadel Pharmaceuticals plc.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Product Portfolio
      • 9.3.10.3. Financial Overview
      • 9.3.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations